OTC · Financial Statements
Eiger BioPharmaceuticals, Inc. (EIGRQ) Financial Statements
$8.50
OTC: EIGRQ
Market Cap $12.59M
Overview Financials Dividend Eiger BioPharmaceuticals, Inc. most recently reported annual revenue of $16.0M, net profit of $-75.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023 Revenue $0 $0 $12.0M $13.0M $16.0M Operating Profit $-69.0M $-62.0M $-77.0M $-93.0M $-72.0M Net Profit $-70.0M $-65.0M $-34.0M $-97.0M $-75.0M EPS $-92.50 $-69.34 $-29.98 $-69.74 $-50.78 Op Margin — — -633.7% -687.8% -455.1%
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023 Total Assets $105.0M $144.0M $127.0M $120.0M $39.0M Total Liabilities $49.0M $49.0M $54.0M $65.0M $53.0M Cash $39.0M $29.0M $22.0M $26.0M $25.0M Borrowings $32.0M $33.0M $33.0M $40.0M $41.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023 Operating Cash Flow $-64.0M $-63.0M $-72.0M $-83.0M $-75.0M Investing Cash Flow $-33.0M $-90.0M $13.0M $19.0M $148.0M Financing Cash Flow $0 $1.0M $0 $-1.0M $0 Net Cash Flow $-22.0M $-11.0M $-7.0M $4.0M $0 Free Cash Flow $-64.0M $-63.0M $-120.0M $-83.0M $-75.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.41 FCF Yield -594.13% Quick Ratio 0.68 Interest Coverage -13.13 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock